Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure

• The FDA has approved Baxter International Inc's (NYSE: BAX) premix norepinephrine bitartrate in 5% dextrose injection.

• Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

• According to a news release, the company's formulation of norepinephrine is the first and only manufacturer-prepared, ready-to-use formulation.

• The Company offers the formulation in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.

• Baxter's formulation has a shelf life of up to 21 months in a refrigerator or up to 90 days at room temperature in overwrap. It can be stored in automated dispensing cabinets at the point of care.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: BAX stock is up 0.12% at $81.15 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies

• RedHill Settles Movantik Patent Litigation With Aurobindo

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.